Foresite Capital Management III’s Larimar Therapeutics LRMR Stock Holding History

Foresite Capital Management III’s Portfolio LRMR Stock Details LRMR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-19,508	Closed	-$822K	–	24
2017 Q2	$822K	Sell	19,508 -11,398	-37%	-$583K	0.27%	21
2017 Q1	$1.73M	Sell	30,906 -8,211	-21%	-$408K	0.66%	21
2016 Q4	$1.49M	Sell	39,117 -5,674	-13%	-$230K	0.65%	15
2016 Q3	$1.78M	Hold	44,791	–	–	0.83%	11
2016 Q2	$3.22M	Sell	44,791 -42,779	-49%	-$3.38M	2.21%	10
2016 Q1	$7.02M	Sell	87,570 -4,072	-4%	-$321K	5.43%	5
2015 Q4	$6.92M	Buy	+91,642	New	+$14.7M	6.13%	5

Other funds holding LRMR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Mangrove Partners Greenwich, Connecticut $1.52B AUM 36.54% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Foresite Capital Management III's LRMR Position: Q3 2017 in Review

Foresite Capital Management III sold out of Larimar Therapeutics (LRMR) in Q3 2017, closing a stake of 19,508 shares — an estimated $822K sold.

Foresite Capital Management III first reported a position in LRMR in Q4 2015 and held it in 7 quarters. The position peaked at $7.02M in Q1 2016. 62 funds tracked by Wall St. Rank hold LRMR as of Q3 2017.

Foresite Capital Management III reported no remaining Larimar Therapeutics position as of Q3 2017 after selling out during the quarter.
Foresite Capital Management III sold 19,508 Larimar Therapeutics shares in Q3 2017, an estimated $822K.
Foresite Capital Management III first reported a position in Larimar Therapeutics in Q4 2015 and held it in 7 quarters.
Foresite Capital Management III's Larimar Therapeutics position peaked at $7.02M in Q1 2016.
62 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q3 2017.

Based on Foresite Capital Management III's 13F filing for Q3 2017, filed 13 Nov 2017.